340B Drug Pricing Program

Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

Retrieved on: 
Monday, August 23, 2021

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m.
  • A replay will be made available on the companys website for six months following the conclusion of the event.
  • IPX-203 is a novel, oral formulation of extended-release CD/LD for patients experiencing motor fluctuations.
  • The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Caravan Health Offers New 340B Services for Medicare and Commercial Claims

Retrieved on: 
Tuesday, July 20, 2021

KANSAS CITY, Mo., July 20, 2021 /PRNewswire-PRWeb/ -- Today, Caravan Health announced a new line of business serving health care providers participating in the 340B drug discount program .

Key Points: 
  • KANSAS CITY, Mo., July 20, 2021 /PRNewswire-PRWeb/ -- Today, Caravan Health announced a new line of business serving health care providers participating in the 340B drug discount program .
  • This new offering will enable covered entities to get the most out of both Medicare and commercial prescription claims for all their patients, regardless of where prescriptions are filled.
  • By participating in 340B, safety-net providers can reach more eligible patients and provide more comprehensive services in their communities.
  • Caravan Health is a privately held company formed to create a sustainable model for health systems to excel in value-based payment models and the 340B drug discount program.

Leading Drug Pricing Experts - Legacy Health Endowment and Powers Law - Collaborate on Series of Issue Papers: Initial Paper Focuses on Intersection of PBMs and the 340B Drug Pricing Program

Retrieved on: 
Tuesday, June 29, 2021

Few Americans are aware, however, that the federal 340B drug pricing program is already providing relief from high drug prices for safety net providers and the communities they serve.

Key Points: 
  • Few Americans are aware, however, that the federal 340B drug pricing program is already providing relief from high drug prices for safety net providers and the communities they serve.
  • Many people also do not know that the 340B program is under attack from both the drug manufacturers selling 340B drugs and the pharmacy benefit managers (PBMs) paying for them.
  • "The 340B program and PBMs are two inextricably linked pieces of the U.S. healthcare system," said Jeffrey Lewis, President, and CEO of Legacy Health Endowment.
  • The firm's drug pricing practice is led by William von Oehsen, one of the architects of the 340B program.

Caravan Health Appoints LeeAnn Scheer as Chief Pharmacy Officer

Retrieved on: 
Thursday, May 20, 2021

b'KANSAS CITY, Mo., May 20, 2021 /PRNewswire-PRWeb/ --Today, Caravan Health announced the hiring of LeeAnn Scheer as Chief Pharmacy Officer.

Key Points: 
  • b'KANSAS CITY, Mo., May 20, 2021 /PRNewswire-PRWeb/ --Today, Caravan Health announced the hiring of LeeAnn Scheer as Chief Pharmacy Officer.
  • Ms. Scheer comes to Caravan with a strong background in helping safety net providers, advocating for rural health, and managing pharmacy supply chains.
  • By participating in 340B, safety net providers can reach more eligible patients and provide more comprehensive services, both of which are critical to succeeding in an ACO.\n"With LeeAnn Scheer on board, Caravan Health is ready to provide more support to our clients in managing their sickest patients," said Tim Gronniger , Caravan Health President and CEO.
  • She joins Caravan from MultiCare Health System, where she served as System Director of Pharmacy Supply Chain and 340B.

340B Program: AHF Salutes Biden Administration for Ordering Six Drug Companies to Restore Price Discounts

Retrieved on: 
Tuesday, May 18, 2021

( HRSA press statement on violation letters ).\n"Thousands of non-profit providers depend on the 340B program to keep their doors open to serve vulnerable populations.

Key Points: 
  • ( HRSA press statement on violation letters ).\n"Thousands of non-profit providers depend on the 340B program to keep their doors open to serve vulnerable populations.
  • 340B costs taxpayers nothing and stretches federal programs that strengthen the healthcare safety net, already severely stressed by a system that enriches the for-profit pharmaceutical industry," said Laura Boudreau, Chief of Operations, Risk Management and Quality Improvement for AHF.
  • "We\'re delighted the Biden Administration has shown it will defend the 340B Program that the pharmaceutical industry tries every day to strangle.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005839/en/\n'

Caravan Health Launches 340B Technology Solution to Improve the Strength and Compliance of the Drug Discount Program

Retrieved on: 
Wednesday, May 5, 2021

Caravan\'s 340B program helps care coordinators learn about these distant visits and manage their subsequent care and prescription medications, improving the quality of patient care and increasing 340B discounts.

Key Points: 
  • Caravan\'s 340B program helps care coordinators learn about these distant visits and manage their subsequent care and prescription medications, improving the quality of patient care and increasing 340B discounts.
  • Caravan\'s proprietary 340B technology automatically prevents non-compliant referral claims from being validated while capturing the documentation needed to validate eligible prescriptions.
  • Through its program of transparency and mutual accountability, Caravan Health has delivered more than 10 times the national average in real savings since 2015.
  • In 2019 and 2020, Caravan Health partners earned $300 million in Medicare savings, over $120 million in shared savings and earned quality scores exceeding 94%.

Chronicled Announces New MediLedger Working Group To Solve Medicaid Duplicate Discounts

Retrieved on: 
Tuesday, April 27, 2021

Multiple pharmaceutical manufacturers have now put in place Medicaid claim requirements and/or 340B discount restrictions in an effort to solve the duplicate discounts problem.

Key Points: 
  • Multiple pharmaceutical manufacturers have now put in place Medicaid claim requirements and/or 340B discount restrictions in an effort to solve the duplicate discounts problem.
  • The goal of the working group is to ensure the success and integrity of the Medicaid and 340B discount programs in serving patients in need.\nThe blockchain-powered MediLedger Network is uniquely suited as the platform for an industry solution to Medicaid duplicate discounts.
  • Data shared with trading partners and rules on the MediLedger network can\'t be changed by any single participant, creating trust even between competitors.\nThe Medicaid Duplicate Discounts Working Group will be the 4th working group launched by Chronicled in collaboration with key stakeholders in the life sciences industry.
  • Previous & ongoing working groups include:\nThe MediLedger Supply Chain Working Group-This group was formed in 2017 around the requirements set forth in the Drug Supply Chain Security Act (DSCSA).

Kalderos' 2021 annual report sets a vision for tech-enabled, patient-centered solutions in Drug Discount Management

Retrieved on: 
Tuesday, April 20, 2021

b'CHICAGO, April 20, 2021 /PRNewswire/ -- Innovative tech company Kalderos today released its 2021 annual report.

Key Points: 
  • b'CHICAGO, April 20, 2021 /PRNewswire/ -- Innovative tech company Kalderos today released its 2021 annual report.
  • During this pivotal moment, it\'s the perfect time to launch our inaugural annual report.
  • More than half of all hospitals who participate in the 340B program now use Kalderos\' provider-facing Discount Monitoring tool.
  • The company\'s product roadmap includes an expansion into data-driven, transparency-minded platform solutions for other drug discount programs.\nTitled "Making health policy work for patients: how platform solutions enable more affordable drugs," the 2021 annual report is freely available to download now .\nKalderos created the world\'s first Drug Discount Management platform, which uses sophisticated models and machine learning to resolve noncompliance in drug discount programs.

The inaugural annual report from Kalderos, a healthcare technology startup, includes data-driven insights on systemic inefficiencies in the drug distribution system and charts the company's rapid growth

Retrieved on: 
Tuesday, April 20, 2021

b'CHICAGO, April 20, 2021 /PRNewswire/ --Innovative tech company Kalderos today released its 2021 annual report.

Key Points: 
  • b'CHICAGO, April 20, 2021 /PRNewswire/ --Innovative tech company Kalderos today released its 2021 annual report.
  • "Industry trends are driving change and so is the massive impact of COVID-19.
  • During this pivotal moment, it\'s the perfect time to launch our inaugural annual report.
  • More than half of all hospitals who participate in the 340B program now use Kalderos\' provider-facing Discount Monitoring tool.

Uncertainty of Government Pricing Policies, Evolution of PBMs, and 340B Program Expansion Identified as Top External Challenges for Pharma Pricing & Contracting Teams This Year

Retrieved on: 
Wednesday, March 3, 2021

The report, based on biopharma companies in varying stages of development, finds that uncertainty of government pricing policies, evolution of pharmacy benefit managers (PBMs) and 340B Program* expansion are the top challenges for contracting teams at biopharma companies this year.

Key Points: 
  • The report, based on biopharma companies in varying stages of development, finds that uncertainty of government pricing policies, evolution of pharmacy benefit managers (PBMs) and 340B Program* expansion are the top challenges for contracting teams at biopharma companies this year.
  • Specifically, people are concerned about the uncertainty around implementation timelines, operational aspects, and overall legitimacy of this legislation.
  • *The 340B Drug Pricing Program is a US federal program that requires pharmaceutical companies to give steep discounts to hospitals and clinics that serve high volumes of low-income patients.
  • Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences.